Phase I clinical trial of Wilms tumor 1 peptide vaccination for patients with advanced cancer

Phase I clinical trial of Wilms tumor 1 peptide vaccination for patients with advanced cancer - Phase I clinical trial of Wilms tumor 1 peptide vaccination

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002771

Enrollment

Registered

2009-11-17

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced cancer

Interventions

WT1 peptide GM-CSF CpG

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: WT1 expression in cancer cells HLA-A2402, A0201, A0206 No severe organ function impairment Written informed consent of the patient Performance Status 0-2

Exclusion criteria

Exclusion criteria: Pregnant female Patient with severe underlying disease Patient with severe allergy disease

Design outcomes

Primary

Measure	Time frame
Safty of WT1 peptide vaccination with / without adjuvant (GM-CSF or CpG)	—

Secondary

Measure	Time frame
Efficacy of WT1 peptide vaccination with / without adjuvant (GM-CSF or CpG)	—

Countries

Japan

Contacts

Public ContactSatoshi Ohno

Waseda University Consolidated Research Institute for Advanced Science and Medical Care

ohno55@aoni.waseda.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026